Source review: 6 October 2026. This is a hypothetical educational scenario, not a verified client engagement or an FDA-approved decision.
No owner-authorized records were available in the inspected repository to substantiate the earlier client engagement, shipment quantities/value, refusal or market-entry timeline. Those claims have been removed. The unspecified botanical cannot be declared FDA-banned or assigned to an import alert on the supplied facts.
First determine what the ingredient and product are
Illustrative scenario: a manufacturer considers a botanical supplement for the US. Document the precise ingredient identity, manufacturing/chemical form, amount, intended population and labeled conditions of use. An ingredient traditionally used abroad is not thereby established as marketed in a US dietary supplement before 15 October 1994. FDA has no authoritative list of all pre-1994 dietary ingredients. Separately assess whether the ingredient and product meet the statutory dietary-ingredient and dietary-supplement definitions, including relevant drug/biologic exclusions; notification does not fix a product outside those definitions.
A new dietary ingredient (NDI) is a dietary ingredient not marketed in the US in a dietary supplement before that date. NDI status, notification obligations and ingredient legality are different questions. The food-supply exception concerns a supplement containing only dietary ingredients present in the food supply as articles used for food in a form not chemically altered. Assess the actual form and all relevant ingredients, not simply a plant’s name or culinary history. Safety responsibility remains even where notification is not required.
FDA background and applicable exceptions: https://www.fda.gov/food/new-dietary-ingredient-ndi-notification-process/new-dietary-ingredients-dietary-supplements-background-industry
A qualifying notification and the conditional 75-day period
Where required, the manufacturer or distributor submits the identity, supplement description, amount, conditions of use and history-of-use or other safety evidence supporting a reasonable expectation of safety. An incomplete submission does not satisfy the notification requirement. Under 21 CFR 190.6, the supplement must not enter interstate commerce for 75 days after the notification filing date; this is not a universal preparation or processing guarantee. FDA determines whether additional material is a substantive amendment; if so, it assigns a new filing date and restarts that period.
Neither receipt acknowledgment, an assigned notification number, silence nor an acknowledgment without objection is FDA safety approval. Review substantive response letters and the actual covered ingredient/form/use. The public notification list is not a comprehensive approval or ban list; absence from it alone cannot establish banned status. Failure to make a required qualifying notification can render the product adulterated, but do not convert that into an unsupported claim that an unidentified ingredient is universally prohibited.
Binding notification regulation: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-B/part-190/subpart-B/section-190.6
FDA’s March 2024 final procedural guidance addresses submission/review procedures and timeframes and contains nonbinding recommendations except where it cites legal requirements. Other related-issues and policy documents identified by FDA as drafts are not final rules or blanket permission to market. Final procedural guidance: https://www.fda.gov/regulatory-information/search-fda-guidance-documents/guidance-industry-new-dietary-ingredient-notification-procedures-and-timeframes-dietary-supplements
Import review: a notice and evidence, not an invented database shortcut
Import Alert 54-18 permits detention without physical examination (DWPE) of identified products from Red List firms. Its guidance also discusses case-by-case evaluation of additions involving a listed NDI offered by another firm. Match the actual product, ingredient, firm and current alert instructions; this scenario asserts no actual listing or agency action. The alert concerns inadequate information providing reasonable assurance about safety under section 402(f)(1)(B), not a universal internal list of ingredients with inactive notifications.
A physical examination or laboratory test is not necessary for every enforcement action. DWPE is distinct from final refusal. Under 21 CFR 1.94, the owner or consignee receives a notice stating the reasons and the place/time for relevant oral or written testimony; a timely, reasonably supported request can seek a changed period/place. Follow the actual deadline. Under this alert, evidence for an individual shipment can show that it is not/does not contain an NDI, or provide relevant safety information such as an appropriate NDIN, to the FDA office specified by the notice. Release evidence and a Red List removal request are separate tasks; submitting an NDIN guarantees neither.
Current Import Alert 54-18: https://www.accessdata.fda.gov/cms_ia/importalert_1158.html
Notice/hearing procedure: https://www.ecfr.gov/current/title-21/chapter-I/subchapter-A/part-1/subpart-E/section-1.94
Illustrative evidence-and-decision worksheet
Recommended workflow, not an FDA form: ingredient identity/form and supplier evidence; US pre-1994 or food-supply evidence; supplement definition and labeled use; safety evidence/gaps; notification applicability and responsible manufacturer/distributor; complete filing/receipt and any substantive-amendment dates; proposed commerce date; any actual entry/notice/charge/deadline; evidence owner, reviewer and dated decision. Mark unresolved facts as unresolved rather than inventing a client outcome.
Illustrative decision: without chemical-form and safety evidence, “traditionally used in China” is insufficient to decide the exception or safety question. Obtain the evidence before making a notification/marketing decision; do not promise an eight-week launch.
Notice-response guide: https://fdabridge.com/blog/fda-import-detention-and-refusal-why-shipments-get-held-and-how-to-prevent-it
An applicable food facility’s registration/2026 renewal is a separate task and does not establish ingredient legality. FDA’s food filing fee is zero; independently agreed professional fees are separate. Renewal guide: https://fdabridge.com/blog/fda-food-facility-registration-renewal-2026
Request a defined assistance scope at https://fdabridge.com/contact . No service guarantees admission or FDA approval.